Skip to contentW
Windtree Therapeutics Inc
W
WINTWindtree Therapeutics Inc Q2 2017 · 10-Q
Revenue$1.15M$1.15M+982.1% vs Q2 2016 Net Income-$6.75M-$6.75MN/M vs Q2 2016 EPS Diluted-$14.37-$14.37N/M vs Q2 2016 Operating Income-$6,140,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Windtree Therapeutics Inc · CIK 946486 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,533,000N/M Margins · derivedOperating margin-535.3%+8892.0 pt vs Q2 2016
Net margin-588.7%+9434.0 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 21, 2017 · 52 d after period end